Advanced Filters
noise
Found 2,203 clinical trials
V Victoria L. Seewaldt

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

This phase III trial evaluates how often women develop insulin resistance and type-2 diabetes and compares metformin with usual care to usual care alone in treating insulin resistance in women with stage I-III breast cancer after chemotherapy. Insulin resistance occurs when cells stop responding to insulin and is a risk …

18 years of age Female Phase 3
A Amanda Gonzalez

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

This phase II trial studies how well imlunestrant and abemaciclib work in treating patients with estrogen receptor positive (ER+) breast cancer who have tumor remaining in the blood following treatment (minimal residual disease). Estrogen can cause the growth of breast cancer cells. Imlunestrant lowers the amount of estrogen made by …

18 years of age All Phase 2
C Clinical Trial Referral Office

Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for early stage breast cancer. Patients undergoing chemotherapy may experience fatigue or nausea as a result of their …

20 years of age All Phase N/A
M Mina S. Sedrak

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called …

years of age Female Phase 2
S Samuel J Haryono, MD

Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment

This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment. Determine the rate of ctDNA positivity at the time before treatment, Determine the rate of ctDNA positivity at the time during …

18 years of age Female Phase N/A

Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer

Phase II study; open recruitment, multicentrique. The aim of this clinical research is to evaluate faisability and toxicity of the per-operative radiotherapy using PAPILLON + TM device for localized breast cancers patients over 65 years.

65 years of age Female Phase 2
A April Riddle, BSRT

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a …

18 years of age Female Phase 1
R Robin Dowell

Study of Screening Brain MRIs in Stage IV Breast Cancer

The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.

18 years of age All Phase N/A
K Katarzyna Jerzak, MD

Using a Blood Test to Monitor Metastatic Breast Cancer Treatment

The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.

18 years of age Female Phase N/A
Y Yen-Ting Liu

Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer

Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy

20 - 85 years of age Female Phase N/A

Simplify language using AI